Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Antibody-Mediated Autoimmune Diseases
NCT02102594Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2014
- Primary completion
- Aug 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in myasthenia gravis (MG), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), sponsored by Charité – Universitätsmedizin Berlin. Started Oct 2014; status: terminated.
02
Drugs
bortezomib
03
Conditions
myasthenia gravis (MG)systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02102594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102594.